PCRX vs. OPK, ALXO, AVIR, ADCT, PRGO, CORT, SUPN, NKTR, OMER, and ASMB
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include OPKO Health (OPK), ALX Oncology (ALXO), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Pacira BioSciences received 312 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.81% of users gave Pacira BioSciences an outperform vote while only 65.61% of users gave OPKO Health an outperform vote.
In the previous week, Pacira BioSciences had 3 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Pacira BioSciences and 3 mentions for OPKO Health. Pacira BioSciences' average media sentiment score of 1.10 beat OPKO Health's score of 0.51 indicating that Pacira BioSciences is being referred to more favorably in the media.
Pacira BioSciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Pacira BioSciences currently has a consensus target price of $47.40, suggesting a potential upside of 65.91%. OPKO Health has a consensus target price of $3.17, suggesting a potential upside of 145.48%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Pacira BioSciences.
Pacira BioSciences has a net margin of 10.34% compared to OPKO Health's net margin of -31.44%. Pacira BioSciences' return on equity of 12.98% beat OPKO Health's return on equity.
99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 47.3% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Pacira BioSciences beats OPKO Health on 13 of the 17 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
